FDA warned tainted syringe maker

FDA sent a warning letter to a North Carolina syringe manufacturer, notifying of "several significant violations" in its quality control system, two years before its needles triggered an outbreak of illnesses that prosecutors say led to at least five deaths, the News & Observer reports. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.